The effects of first-line anti-tuberculosis drugs on the actions of vitamin D in human macrophages

被引:18
|
作者
Chesdachai, Supavit [1 ,2 ]
Zughaier, Susu M. [1 ,2 ]
Hao, Li [1 ,2 ]
Kempker, Russell R. [1 ,2 ]
Blumberg, Henry M. [1 ,2 ]
Ziegler, Thomas R. [1 ,2 ]
Tangpricha, Vin [1 ,2 ]
机构
[1] Emory Univ, Sch Med, Dept Med, Div Endocrinol Metab & Lipids, 101 Woodruff Circle NE WMRB1301, Atlanta, GA 30322 USA
[2] Atlanta VA Med Ctr, 101 Woodruff Circle NE WMRB1301, Atlanta, GA 30322 USA
来源
JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY | 2016年 / 6卷
基金
美国国家卫生研究院;
关键词
Vitamin D; Tuberculosis; Cathelicidin; Antibiotics;
D O I
10.1016/j.jcte.2016.08.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tuberculosis (TB) is a major global health problem. Patients with TB have a high rate of vitamin D deficiency, both at diagnosis and during the course of treatment with anti-tuberculosis drugs. Although data on the efficacy of vitamin D supplementation on Mycobacterium tuberculosis (Mtb) clearance are uncertain from randomized controlled trials (RCTs), vitamin D enhances the expression of the antimicrobial peptide human cathelicidin (hCAP18) in cultured macrophages in vitro. One possible explanation for the mixed (primarily negative) results of RCTs examining vitamin D treatment in TB infection is that anti-TB drugs given to enrolled subjectsmay impact actions of vitamin D to enhance cathelicidin in macrophages. To address this hypothesis, human macrophage-like monocytic (THP-1) cellswere treated with varying doses of first-line anti-tuberculosis drugs in the presence of the active form of vitamin D, 1,25dihydroxyvitamin D-3 (1,25(OH) 2D(3)). The expression of hCAP18 was determined by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). 1,25(OH)(2)D-3 strongly induced expression of hCAP18 mRNA in THP-1 cells (fold-change fromcontrol). The combination of the standard 4-drug TB therapy (isoniazid, rifampicin, pyrazinamide and ethambutol) in the cultured THP-1 cells demonstrated a significant decrease in hCAP18 mRNA at the dosage of 10 mu g/ mL. In 31 subjects with newly diagnosed drugsensitive TB randomized to either high-dose vitamin D-3 (1.2 million IU over 8weeks, n = 13) versus placebo (n = 18), there was no change from baseline to week 8 in hCAP18 mRNA levels in peripheral blood mononuclear cells or in plasma concentrations of LL-37, the protein product of hCAP18. These data suggest that first-line anti-TB drugs may alter the vitamin D-dependent increase in hCAP18 and LL-37 human macrophages. Published by Elsevier Inc.
引用
收藏
页码:23 / 29
页数:7
相关论文
共 50 条
  • [31] High occurrence of simultaneous multiple-drug hypersensitivity syndrome induced by first-line anti-tuberculosis drugs
    Sim, Da Woon
    You, Hye Su
    Yu, Ji Eun
    Koh, Young-Il
    WORLD ALLERGY ORGANIZATION JOURNAL, 2021, 14 (07):
  • [32] Simultaneous determination of first-line anti-tuberculosis drugs by capillary zone electrophoresis using direct UV detection
    Faria, Adriana F.
    de Souza, Marcus V. N.
    Bruns, Roy E.
    de Oliveira, Marcone A. L.
    TALANTA, 2010, 82 (01) : 333 - 339
  • [33] Simultaneous analysis of first-line anti-tuberculosis drugs in tablets by UV spectrophotometry compared to capillary zone electrophoresis
    Marcellos, Luiza F.
    Faria, Adriana F.
    de Souza, Marcus V. N.
    Almeida, Mariana R.
    Sabin, Guilherme P.
    Poppi, Ronei J.
    de Oliveira, Marcone A. L.
    CENTRAL EUROPEAN JOURNAL OF CHEMISTRY, 2012, 10 (06): : 1808 - 1816
  • [34] Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study
    Prahl, Julie B.
    Johansen, Isik S.
    Cohen, Arieh S.
    Frimodt-Moller, Niels
    Andersen, Ase B.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (10) : 2841 - 2847
  • [35] Toxicity of the Increased Recommended Doses of First-line Anti-tuberculosis Oral Drugs in Children in a Reference Center in Spain
    Pereira, Laura
    Marco-Garcia, Monica
    Gamell, Anna
    Cuso, Teresa
    Monsonis, Manuel
    Latre, Cristina
    Fortuny, Claudia
    Noguera-Julian, Antoni
    ARCHIVOS DE BRONCONEUMOLOGIA, 2023, 59 (09): : 612 - 615
  • [36] Isonicotinylation is a histone mark induced by the anti-tuberculosis first-line drug isoniazid
    Yuhan Jiang
    Yixiao Li
    Cheng Liu
    Lei Zhang
    Danyu Lv
    Yejing Weng
    Zhongyi Cheng
    Xiangmei Chen
    Jun Zhan
    Hongquan Zhang
    Nature Communications, 12
  • [37] Isonicotinylation is a histone mark induced by the anti-tuberculosis first-line drug isoniazid
    Jiang, Yuhan
    Li, Yixiao
    Liu, Cheng
    Zhang, Lei
    Lv, Danyu
    Weng, Yejing
    Cheng, Zhongyi
    Chen, Xiangmei
    Zhan, Jun
    Zhang, Hongquan
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [38] Adverse drug reactions associated with first-line anti-tuberculosis drug regimens
    Marra, F.
    Marra, C. A.
    Bruchet, N.
    Richardson, K.
    Moadebi, S.
    Elwood, R. K.
    FitzGerald, J. M.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2007, 11 (08) : 868 - 875
  • [39] Incidence and outcomes of adverse drug reactions to first-line anti-tuberculosis drugs and their effects on the quality of life: A multicenter prospective cohort study
    Choi, Hayoung
    Park, Hang A.
    Hyun, In Gyu
    Kim, Joo-Hee
    Hwang, Yong-Il
    Jang, Seung Hun
    Sim, Yun Su
    Shin, Tae Rim
    Ko, Yousang
    Ban, Ga Young
    Hong, Ji Young
    Lee, Chang Youl
    Lee, Myung Goo
    Choi, Jeong-Hee
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 (11) : 1153 - 1163
  • [40] Vitamin D supplementation as adjunct to anti-tuberculosis drugs in Mongolian TB patients
    Davaasambuu, Ganmaa
    Bromage, Sabri
    Erkhembayar, Baasansuren
    Jaisandavga, Erdenetseg
    Baatar, Munkhzul
    FASEB JOURNAL, 2015, 29